Want to see ESTA full AI Analyst Report?
ESTA Stock Chart & Stats
$71.80
-$0.46(-0.50%)
At close: 4:00 PM EDT
$71.80
-$0.46(-0.50%)
Day’s Range― - ―
52-Week Range$36.53 - $97.59
Previous CloseN/A
Volume49.76K
Average Volume (3M)491.09K
Market Cap
$2.21B
Enterprise Value$2.78K
Total Cash (Recent Filing)$71.16M
Total Debt (Recent Filing)$263.67M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 10, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding29,801,891
10 Day Avg. Volume364,444
30 Day Avg. Volume491,094
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)91.68
Price to Sales (P/S)10.23
P/FCF Ratio-37.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$101.71Price Target Upside41.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.2
Revenue Forecast (FY)$270.15M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Gross MarginThe company is building meaningful revenue scale while retaining strong gross margins, indicating that its Motiva implant business can support substantial gross profit as sales expand. Continued growth would improve operating leverage and provide a stronger base for funding commercial expansion and future profitability.
Low Current Debt BurdenVery low reported debt reduces near-term interest and refinancing pressure, giving management more flexibility while the business works toward profitability. The sharp improvement from prior high leverage also lowers balance-sheet risk and preserves capacity to use future cash flows for growth rather than debt service.
Losses And Cash Burn Are ImprovingAlthough the company remains loss-making, the substantial reduction in net losses shows progress toward operating breakeven. Improvement in free-cash-flow burn also suggests better efficiency or tighter investment spending, which could extend financial flexibility if the trend continues over coming quarters.
Bears Say
Profitability Remains NegativeStrong gross margins have not yet translated into positive operating or net earnings, showing that operating expenses still exceed gross profit. Sustained losses limit internally generated capital, delay durable returns for shareholders, and leave execution on growth and cost control central to the investment case.
Persistent Negative Cash GenerationRepeatedly negative operating cash flow means the business is not yet funding its operations from internally generated cash. Continued free-cash-flow deficits can require external funding or use of balance-sheet flexibility, potentially constraining investment choices until sustainable cash breakeven is achieved.
Thin Equity BaseThe relatively small equity cushion compared with total assets leaves less structural protection against continued losses or operating setbacks. Deeply negative returns on equity further show that capital is not currently generating shareholder returns, making restoration of profitability important for long-term balance-sheet strength.
Establishment Labs Holdings News
ESTA FAQ
What was Establishment Labs Holdings Inc’s price range in the past 12 months?
Establishment Labs Holdings Inc lowest stock price was $36.53 and its highest was $97.59 in the past 12 months.
What is Establishment Labs Holdings Inc’s market cap?
Establishment Labs Holdings Inc’s market cap is $2.21B.
When is Establishment Labs Holdings Inc’s upcoming earnings report date?
Establishment Labs Holdings Inc’s upcoming earnings report date is Nov 10, 2026 which is in 64 days.
How were Establishment Labs Holdings Inc’s earnings last quarter?
Establishment Labs Holdings Inc released its earnings results on Aug 06, 2026. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.337 by -$0.053.
Is Establishment Labs Holdings Inc overvalued?
According to Wall Street analysts Establishment Labs Holdings Inc’s price is currently Undervalued.
Does Establishment Labs Holdings Inc pay dividends?
Establishment Labs Holdings Inc does not currently pay dividends.
What is Establishment Labs Holdings Inc’s EPS estimate?
Establishment Labs Holdings Inc’s EPS estimate is -0.26.
How many shares outstanding does Establishment Labs Holdings Inc have?
Establishment Labs Holdings Inc has 29,801,891 shares outstanding.
What happened to Establishment Labs Holdings Inc’s price movement after its last earnings report?
Establishment Labs Holdings Inc reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.337. Following the earnings report the stock price went down -13.37%.
Which hedge fund is a major shareholder of Establishment Labs Holdings Inc?
Currently, no hedge funds are holding shares in ESTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Establishment Labs Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$101.71 (41.66% Upside)
$101.71 (41.66% Upside)
Blogger Sentiment
Bullish
ESTA Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 119.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
ESTA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and commercial momentum led by a rapid U.S. launch, 45% YoY revenue growth in Q1, improving gross margin (70.7%) and a return to positive adjusted EBITDA. Key product innovations (minimally invasive platform) are driving adoption, surgeon and patient demand, and management raised full-year revenue guidance. Offsetting factors include elevated operating expenses, near-term cash usage and increased debt with PIK mechanics, plus some supply and geopolitical uncertainties. Overall, the positives around revenue acceleration, margin expansion, product differentiation and pathway to cash-flow positivity materially outweigh the risks discussed.View all ESTA earnings summariesESTA Stock 12 Month Forecast
Average Price Target
$101.71
▲(41.66% Upside)
Technical Analysis
Ownership Overview
17.80% Insiders
5.95% Mutual Funds
49.67% Other Institutional Investors
20.41% Public Companies and
Individual Investors